BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 22414856)

  • 1. Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.
    Liu Y; Webb HK; Fukushima H; Micheli J; Markova S; Olson JL; Kroetz DL
    J Pharmacol Exp Ther; 2012 Jun; 341(3):725-34. PubMed ID: 22414856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.
    Liu Y; Lu X; Nguyen S; Olson JL; Webb HK; Kroetz DL
    Mol Pharmacol; 2013 Dec; 84(6):925-34. PubMed ID: 24092818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.
    Fife KL; Liu Y; Schmelzer KR; Tsai HJ; Kim IH; Morisseau C; Hammock BD; Kroetz DL
    J Pharmacol Exp Ther; 2008 Dec; 327(3):707-15. PubMed ID: 18815352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in soluble epoxide hydrolase (sEH) during cisplatin-induced acute renal failure in mice.
    Hashimoto T; Fang YI; Ohata H; Honda K
    J Toxicol Sci; 2015 Aug; 40(4):451-7. PubMed ID: 26165641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
    Chen G; Xu R; Wang Y; Wang P; Zhao G; Xu X; Gruzdev A; Zeldin DC; Wang DW
    Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E563-75. PubMed ID: 22739108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.
    Motoki A; Merkel MJ; Packwood WH; Cao Z; Liu L; Iliff J; Alkayed NJ; Van Winkle DM
    Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2128-34. PubMed ID: 18835921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase.
    Parrish AR; Chen G; Burghardt RC; Watanabe T; Morisseau C; Hammock BD
    Cell Biol Toxicol; 2009 Jun; 25(3):217-25. PubMed ID: 18386137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice.
    Zhu Y; Blum M; Hoff U; Wesser T; Fechner M; Westphal C; Gürgen D; Catar RA; Philippe A; Wu K; Bubalo G; Rothe M; Weldon SM; Dragun D; Schunck WH
    PLoS One; 2016; 11(1):e0145645. PubMed ID: 26727266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
    Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
    Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-ribose ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice.
    Ueki M; Ueno M; Morishita J; Maekawa N
    Tohoku J Exp Med; 2013 Mar; 229(3):195-201. PubMed ID: 23438786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling.
    Merkel MJ; Liu L; Cao Z; Packwood W; Young J; Alkayed NJ; Van Winkle DM
    Am J Physiol Heart Circ Physiol; 2010 Feb; 298(2):H679-87. PubMed ID: 20008276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury.
    Bettaieb A; Koike S; Chahed S; Zhao Y; Bachaalany S; Hashoush N; Graham J; Fatima H; Havel PJ; Gruzdev A; Zeldin DC; Hammock BD; Haj FG
    FEBS J; 2017 Jul; 284(13):1970-1986. PubMed ID: 28485854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Epoxide Hydrolase Inhibitor Attenuates Lipopolysaccharide-Induced Acute Lung Injury and Improves Survival in Mice.
    Zhou Y; Liu T; Duan JX; Li P; Sun GY; Liu YP; Zhang J; Dong L; Lee KSS; Hammock BD; Jiang JX; Guan CX
    Shock; 2017 May; 47(5):638-645. PubMed ID: 27753791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Epoxide Hydrolase Inhibition Attenuates Excitotoxicity Involving 14,15-Epoxyeicosatrienoic Acid-Mediated Astrocytic Survival and Plasticity to Preserve Glutamate Homeostasis.
    Kuo YM; Hsu PC; Hung CC; Hu YY; Huang YJ; Gan YL; Lin CH; Shie FS; Chang WK; Kao LS; Tsou MY; Lee YH
    Mol Neurobiol; 2019 Dec; 56(12):8451-8474. PubMed ID: 31257558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA.
    Diani-Moore S; Ma Y; Gross SS; Rifkind AB
    Drug Metab Dispos; 2014 Feb; 42(2):294-300. PubMed ID: 24311719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.
    Revermann M; Schloss M; Barbosa-Sicard E; Mieth A; Liebner S; Morisseau C; Geisslinger G; Schermuly RT; Fleming I; Hammock BD; Brandes RP
    Arterioscler Thromb Vasc Biol; 2010 May; 30(5):909-14. PubMed ID: 20224052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
    Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL
    Circ Res; 2000 Nov; 87(11):992-8. PubMed ID: 11090543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.
    Elmarakby AA; Faulkner J; Pye C; Rouch K; Alhashim A; Maddipati KR; Baban B
    Clin Sci (Lond); 2013 Oct; 125(7):349-59. PubMed ID: 23611540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.
    Kim J; Yoon SP; Toews ML; Imig JD; Hwang SH; Hammock BD; Padanilam BJ
    Am J Physiol Renal Physiol; 2015 Jan; 308(2):F131-9. PubMed ID: 25377915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble epoxide hydrolase: a novel therapeutic target in stroke.
    Zhang W; Koerner IP; Noppens R; Grafe M; Tsai HJ; Morisseau C; Luria A; Hammock BD; Falck JR; Alkayed NJ
    J Cereb Blood Flow Metab; 2007 Dec; 27(12):1931-40. PubMed ID: 17440491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.